Celltrion said that it has launched two diagnostic kits of Covid-19 -- Sampinute COVID-19 Antigen MIA and DiaTrust COVID-19 IgG/IgM Rapid Test -- in the U.S.
Celltrion has recently launched two Covid-19 diagnostic kits, Sampinute COVID-19 Antigen MIA (left) and DiaTrust COVID-19 IgG/IgM Rapid Test, in the U.S. (Celltrion) |
The company has actively collaborated with specialized companies since February to commercialize diagnostic kits that can meet global market demand and recently completed developing the products.
Sampinute COVID-19 Antigen MIA is a point-of-care testing (POCT) kit for the detection of Covid-19 antigen from nasopharyngeal swab samples in collaboration with BBB. The equipment is composed of a one-time-use test cartridge and a portable analyzer. It takes about 10 minutes for the user to confirm their results.
According to the company, the device also has a higher sensitivity than reverse the transcription-polymerase chain reaction (RT-PCR) test kits.
DiaTrust COVID-19 IgG/IgM Rapid Test is a one-step antibody rapid diagnostic test (RDT) developed in collaboration with Humasis. The device is based on an immunochromatographic assay designed for the rapid detection of Covid-19 antibodies.
"Antibody RDT can test a large number of patients at a low cost easily," the company said. "We believe it can play a complementary role with antigen POCT, and plans to sell the two products in a bundled package to maximize marketability."
Celltrion is also working with Humasis to develop improved antibody and antigen RDT with higher sensitivity.
"By working with promising Korean companies to develop a Covid-19 diagnostic kit, the company has managed to enter into the world's largest medical market," a company official said. "We hope we will help put an end to the pandemic in the U.S. through our quality products."
corea022@docdocdoc.co.kr
<© Korea Biomedical Review, All rights reserved.>